Inhibition of glyceraldehyde-3-phosphate dehydrogenase in post-ischaemic myocardium (original) (raw)
Journal Article
,
aaDepartment of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095-6948, USA
Search for other works by this author on:
,
bbDepartment of Cardiology B 2142, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other works by this author on:
,
aaDepartment of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095-6948, USA
Search for other works by this author on:
aaDepartment of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095-6948, USA
*Corresponding author. Tel.: (+1-310) 825-2843; fax: (+ 1-310) 825-4517.
Search for other works by this author on:
Received:
05 February 1996
Published:
01 December 1996
Cite
Richard J Knight, Klaus F Kofoed, Heinrich R Schelbert, Denis B Buxton, Inhibition of glyceraldehyde-3-phosphate dehydrogenase in post-ischaemic myocardium, Cardiovascular Research, Volume 32, Issue 6, December 1996, Pages 1016–1023, https://doi.org/10.1016/S0008-6363(96)00137-X
Close
Navbar Search Filter Mobile Enter search term Search
Abstract
Objective:
Myocardial reperfusion following brief periods of ischaemia is associated with prolonged, reversible periods of metabolic dysfunction. As the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is inhibited in vitro by reactive oxygen species, we hypothesized that production of reactive oxygen species during reperfusion would lead to inhibition of GAPDH in post-ischaemic myocardium. Methods: Anaesthetized closed-chest dogs were subjected to 20 min balloon occlusion of the left anterior descending coronary artery. Biopsy samples were taken after 3 and 24 h of reperfusion, to determine the activity of GAPDH and the concentrations of glycolytic intermediates in post-ischaemic and remote, non-ischaemic territories. Results: A significant reduction in GAPDH activity was observed in post-ischaemic relative to remote tissue after 3 h reperfusion (4.8 ± 0.5 vs. 2.9 ± 0.2 μmol/min/mg protein; P < 0.01). Western blotting revealed no reduction in the levels of GAPDH protein. Analysis of enzyme kinetics showed the loss of activity to be associated with decreased _V_max (5.9 ± 0.5 vs. 3.2 ± 0.2 μmol/min/mg protein; P < 0.01) with no significant change in the _K_m for glyceraldehyde-3-phosphate (GAP). Incubation of the inhibited enzyme under both mild and strong reducing conditions failed to reactivate the enzyme. The acute reduction in enzyme activity in post-ischaemic tissue was accompanied by regional differences in glycolytic intermediates, notably a twofold accumulation of GAP (P < 0.05), and a reduction in the glucose metabolic rate (GMR) determined by positron emission tomography and [18F]2-fluorodeoxyglucose. By 24 h reperfusion, no regional differences in GAPDH activity, reaction _V_max or _K_m, GAP concentrations or GMR were detectable. Conclusions: These results suggest that inhibition of GAPDH activity may represent an important point at which glycolysis is limited during reperfusion, and further, that the mechanisms of enzyme inhibition do not involve simple oxidation or _S_-thiolation of critical active site thiol groups.
This content is only available as a PDF.
Copyright © 1996, European Society of Cardiology
Topic:
- myocardium
- positron-emission tomography
- ischemia
- anterior descending branch of left coronary artery
- western blotting
- oxidation
- reperfusion therapy
- physiologic reperfusion
- biopsy
- glucose
- balloon occlusion
- dog, domestic
- glyceraldehyde 3-phosphate
- glyceraldehyde-3-phosphate dehydrogenases
- glycolysis
- myocardial reperfusion
- reactive oxygen species
- sulfhydryl compounds
- enzymes
- chest
- enzyme kinetics
- metabolic disturbance
- geographic difference
- metabolic rate
- enzyme activity
Advertisement intended for healthcare professionals
Citations
Views
Altmetric
Metrics
Total Views 2,244
26 Pageviews
2,218 PDF Downloads
Since 2/1/2017
Month: | Total Views: |
---|---|
February 2017 | 5 |
March 2017 | 2 |
May 2017 | 3 |
August 2017 | 1 |
September 2017 | 2 |
October 2017 | 3 |
November 2017 | 7 |
December 2017 | 12 |
January 2018 | 11 |
February 2018 | 10 |
March 2018 | 21 |
April 2018 | 28 |
May 2018 | 32 |
June 2018 | 18 |
July 2018 | 15 |
August 2018 | 13 |
September 2018 | 5 |
October 2018 | 20 |
November 2018 | 16 |
December 2018 | 21 |
January 2019 | 6 |
February 2019 | 18 |
March 2019 | 56 |
April 2019 | 85 |
May 2019 | 30 |
June 2019 | 19 |
July 2019 | 24 |
August 2019 | 17 |
September 2019 | 27 |
October 2019 | 63 |
November 2019 | 43 |
December 2019 | 31 |
January 2020 | 34 |
February 2020 | 54 |
March 2020 | 55 |
April 2020 | 99 |
May 2020 | 40 |
June 2020 | 35 |
July 2020 | 73 |
August 2020 | 36 |
September 2020 | 43 |
October 2020 | 78 |
November 2020 | 119 |
December 2020 | 44 |
January 2021 | 30 |
February 2021 | 63 |
March 2021 | 71 |
April 2021 | 105 |
May 2021 | 25 |
June 2021 | 19 |
July 2021 | 18 |
August 2021 | 23 |
September 2021 | 18 |
October 2021 | 43 |
November 2021 | 35 |
December 2021 | 25 |
January 2022 | 33 |
February 2022 | 22 |
March 2022 | 19 |
April 2022 | 20 |
May 2022 | 12 |
June 2022 | 14 |
July 2022 | 24 |
August 2022 | 15 |
September 2022 | 93 |
October 2022 | 25 |
November 2022 | 1 |
December 2022 | 2 |
January 2023 | 4 |
February 2023 | 4 |
March 2023 | 1 |
April 2023 | 4 |
May 2023 | 3 |
June 2023 | 1 |
August 2023 | 3 |
September 2023 | 2 |
November 2023 | 5 |
December 2023 | 4 |
January 2024 | 1 |
February 2024 | 2 |
March 2024 | 9 |
April 2024 | 24 |
May 2024 | 12 |
June 2024 | 14 |
July 2024 | 9 |
August 2024 | 8 |
September 2024 | 5 |
Citations
47 Web of Science
×
Email alerts
Related articles in PubMed
Citing articles via
More from Oxford Academic
Advertisement intended for healthcare professionals